The use of phosphodiesterase 5 inhibitors with concomitant medications.
about
Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors.Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidencePolypharmacy in the HIV-infected older adult population.Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes?Erectile dysfunction as a marker for cardiovascular disease diagnosis and intervention: a cost analysis.Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.Phosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsEfficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis.Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives.Late onset hypogonadism, sexuality and fertility.ADMET considerations for phosphodiesterase-5 inhibitors.Sildenafil: two decades of benefits or risks?Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis.First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis.EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil.Erectile dysfunction
P2860
Q28554489-F37F1B7B-0AA0-4C26-8EE9-B43A232AF2D8Q33571010-7CBB4556-D75B-4DFB-B7DE-85C8B9ED5F03Q34037407-F346E9A1-2B49-49AF-ACAE-BDC7478DECE0Q34987666-686E0FEA-8465-45C0-9378-B9BC8D3E41A5Q35328376-7E7FD267-C248-4A3B-9EE8-4ED010A4A5D6Q35850118-6FF4BE40-2898-405F-9F65-040A5DD86E42Q36460566-DCD9DDDF-AEE1-4230-829E-4D408AB8595FQ37074999-B24E48B9-7663-4FB1-A60D-0B747D7A2BA6Q37686844-44C56AF0-1DE6-4A08-A0E1-B1F3FB996399Q37789736-375D1BBE-DEF0-4712-AE2E-2B30B775AC79Q38024409-97908D0C-AFDF-45AF-9EC4-8DFD57969101Q38113844-FD5138CD-DC2B-454E-ADF0-B5FE25C1807DQ38241416-FDBBC781-807C-4E7E-8487-A6C06C2851DCQ38956366-DDD72E0A-3F7F-4446-9E5A-2E10A2C7AE6CQ48529608-CAEBCFDD-D548-41F4-83E7-349D3A5B9EFEQ56966121-9E3600C2-8B01-466A-8F50-EEBAD435C255
P2860
The use of phosphodiesterase 5 inhibitors with concomitant medications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The use of phosphodiesterase 5 inhibitors with concomitant medications.
@en
The use of phosphodiesterase 5 inhibitors with concomitant medications.
@nl
type
label
The use of phosphodiesterase 5 inhibitors with concomitant medications.
@en
The use of phosphodiesterase 5 inhibitors with concomitant medications.
@nl
prefLabel
The use of phosphodiesterase 5 inhibitors with concomitant medications.
@en
The use of phosphodiesterase 5 inhibitors with concomitant medications.
@nl
P2093
P2860
P356
P1476
The use of phosphodiesterase 5 inhibitors with concomitant medications
@en
P2093
P2860
P2888
P304
P356
10.1007/BF03349261
P50
P577
2008-09-01T00:00:00Z